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Abstract In Alzheimer’s disease, neurofibrillary degeneration
results from the aggregation of abnormally phosphorylated Tau
proteins into paired helical filaments. These Tau variants
displayed specific epitopes that are immunoreactive with anti-
phospho-Tau antibodies such as AT100. As shown in in vitro
experiments, glycogen synthase kinase 3 L (GSK3L) and protein
kinase A (PKA) may be key kinases in these phosphorylation
events. In the present study, Tau was microinjected into Xenopus
oocytes. Surprisingly, in this system, AT100 was generated
without any GSK3L and PKA contribution during the
progesterone or insulin-induced maturation process. Our results
demonstrate that a non-modified physiological process in a cell
model can generate the most specific Alzheimer epitope of Tau
pathology. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Abnormal phosphorylation is the major posttranslational
modi¢cation of Tau proteins aggregated into paired helical
¢laments (PHF) in Alzheimer’s disease (AD). Despite the
fact that many phosphorylation sites are common between
PHF-Tau and normal Tau in control-biopsy material, there
are now evidences of an abnormal phosphorylation in AD
(for review see [1]). For instance, phosphorylated Tau aggre-
gated into ¢laments but not normal Tau can be visualised by
AT100 antibody that recognises a conformation-dependent
epitope [2]. In vitro, AT100 epitope appears after a long and
sequential phosphorylation by glycogen synthase kinase 3 L
(GSK3L) and protein kinase A (PKA) in the presence of
heparin [2]. In cell models, this phospho-epitope appears
only after treatment with okadaic acid (OA) [3,4] suggesting
that inhibition of PP2A and or PP1 is necessary for AT100
genesis. To investigate the physiological Tau phosphorylation
in vivo, Tau proteins were microinjected into Xenopus oocytes
as described previously [5].
In fact, Xenopus oocytes are arrested at prophase of the ¢rst
division of meiosis (prophase I). In response to progesterone,
oocytes undergo meiosis (also named maturation) [6,7], which
can be followed by the appearance of a white spot (WS) at the
animal pole. Many kinases are involved in the cytological
events that characterise oocyte maturation; some of them
have to be activated whereas others must be inhibited (Fig.
1A). First, it is well known that PKA activity is maintained at
a high level in immature oocytes and drops following proges-
terone stimulation [8]. Similarly, it has been recently demon-
strated that GSK3L activity follows a similar regulation [9].
Conversely, maturation requires protein kinase activation.
For instance, when activated, MAPK and p34Cdc2 are respon-
sible for the morphological changes accompanying maturation
such as germinal vesicle breakdown (GVBD), chromosome
condensation and spindle formation [10,11]. So, Xenopus
oocytes possess many of the kinases that could be involved
in Tau phosphorylation that occurs in AD. Thus, we took
advantage of this model to study the AT100 immunoreactiv-
ity. Using anti-Tau antibodies directed against phosphoryla-
tion-dependent or phosphorylation-independent epitopes, the
state of phosphorylation of recombinant Tau proteins was
investigated by immunoblotting after their injection into Xe-
nopus oocytes. Our results showed that neither GSK3L nor
PKA were necessary for AT100 appearance in this system.
Therefore, Xenopus oocytes could be used as a model to iden-
tify the kinases that are involved in the pathological phos-
phorylation of Tau proteins that are found in AD and several
neurodegenerative disorders.
2. Materials and methods
2.1. Experimental conditions
The 2+3^10+ isoform of human brain Tau (ht412) was expressed in
Escherichia coli from cDNA clone htau46 [12] and puri¢ed as de-
scribed [13]. Recombinant Tau proteins or bu¡er alone were micro-
injected in oocytes at a constant volume of 50 nl per stage VI oocyte
by the use of a positive displacement digital micropipette (Nichiryo)
as previously described [5].
Maturation was induced in ND96 medium (96 mM NaCl, 2 mM
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES/NaOH, pH 7.5) by
progesterone addition (10 WM) [14] or in K-free OR2 medium [15] in
the case of insulin stimulation (1 WM). The hormone was always
added 1 h after the injection of ht412 or drug application to allow
di¡usion in the oocyte due to its sise (1.2 mm in diameter). Matura-
tion was determined either by WS detection or by microscopic exami-
nation of dissected heat-treated oocytes (100‡C, 3 min).
LiCl (10 or 20 mM) was used to inhibit GSK3L [16], and oocytes
were maintained in this medium from 2 h before the microinjection of
ht412 until the end of the experiment.
Inhibition of PKA was performed by injection of the PKA regula-
tory subunit (PKAr) (Promega, France) [17].
2.2. Antibodies
Phosphorylation-dependent monoclonal antibodies included AD2
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directed against phosphorylated Ser396^404 [18], and Tau-1 that
binds amino acids 189^207 only when they are dephosphorylated
[19]. AT100 was used to detect abnormal Tau phosphorylation [2].
Finally, M19G is a well-characterised anti-serum, directed against the
¢rst 19 amino acids of the tau sequence encoded by exon 1 [18] that
recognises its epitope independently of the Tau phosphorylation state.
Other antibodies used are a home-made polyclonal anti-tubulin and a
polyclonal antibody against human L-catenin (H-102) (Santa Cruz
Biotechnology).
2.3. Electrophoresis and Western blotting
Depending on the experiment, 5^20 oocytes were homogenised in
homogenisation bu¡er (MOPS 25 mM pH 7.2 with protease and
phosphatase inhibitors [20], 10 Wl per oocyte) and centrifuged for 5
min at 13 000Ug (4‡C) to eliminate yolk platelets. Proteins were then
analysed by immunoblotting [5]. Densitometry analyses allowed for
the quanti¢cation of L-catenin as described for Tau in [5].
2.4. Controls
Hyperphosphorylated ht412 was obtained following htau46 cDNA
transfection in COS cells and cell treatment with OA as previously
described [4]. This cell lysate and brain homogenate from an Alzhei-
mer patient were used as a positive control for phosphorylation-de-
pendent Tau antibodies.
3. Results
As previously described [5], oocyte injection of 50 ng
htau412 did not interfere with maturation (Fig. 1A). This
concentration was kept for all further experiments. An anal-
ysis of Tau solubility following microinjection revealed that
these proteins were found in the 13 000Ug supernatant not
only in homogenates from prophase I but also in progester-
one- or insulin-treated ones (Fig. 1B,C). So, all subsequent
analyses were performed in these fractions. Moreover, it
should be noted that Tau proteins showed di¡erent states of
phosphorylation during oocyte maturation. In prophase I-ar-
rested oocytes, Tau proteins exhibited an apparent Mr at
about 61 kDa and were detected with the polyclonal anti-
Tau antibody (M19G) and Tau-1 monoclonal antibody but
not with the phosphorylation-dependent antibodies AD2 or
AT100. 8 h after Tau microinjection into oocyte and without
progesterone or insulin-induced maturation, Tau displayed an
intermediary Mr at 65 kDa as visualised by AD2 and M19G
antibodies. However, there was no AT100-immunoreactivity
(Fig. 1B). Conversely, in metaphase II oocytes, after proges-
terone- (8 h) or insulin-induced (12 h) maturation (Fig. 1B,C),
htau412 migrated at 69 kDa and was recognised by both anti-
Fig. 1. htau412 phosphorylation during Xenopus oocyte maturation.
A: Typical representation of progesterone-induced oocyte matura-
tion. The maturation is visualised by the WS appearance with (U)
(50 ng) and without (F) tau injection. GSK3L and PKA are both
active in prophase I oocytes and inactivated after progesterone stim-
ulation. In meiosis I, a number of kinases are activated including
Cdc2 and MAPK. Other kinases may be activated during GVBD
such as Cdk2. B,C: Immunoblotting analysis of tubulin and
htau412 phosphorylation in prophase I (3) and metaphase II-ar-
rested Xenopus oocytes (+). Phosphorylation states of Tau proteins
were visualised by M19G, AD2 and AT100 antibodies during pro-
gesterone (B)-, or insulin (C)-induced maturation. Note that both
Tau proteins and Xenopus tubulin are in the same soluble fraction
and that insulin maturation is longer (12 h) than with progesterone
(8 h). Mrs are indicated at the right side of the ¢gure.
Fig. 2. E¡ect of the GSK3L inhibitor LiCl on htau412 phosphorylation. A time-course experiment was performed in prophase I oocytes after
Tau injection in the presence (+) or absence of LiCl (3). Each experiment was compared to Tau protein in metaphase II extract. AD2 recog-
nises a GSK3L epitope. M19G is a polyclonal anti-Tau antibody.
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bodies AD2 and AT100, indicating that Tau proteins showed
an abnormal phosphorylation pro¢le during maturation pro-
cess. However, there was a complete loss of Tau-1 immuno-
reactivity (data not shown).
In the Xenopus oocyte model, GSK3L and PKA are both
active in immature oocytes (prophase I) [8,9]. Moreover, both
kinases must be inactivated to allow oocyte maturation. How-
ever, not only the 69 kDa shift of htau412 but also the AT100
staining was observed in metaphase II oocytes. Furthermore,
insulin was shown to inactivate GSK3L by the pKB/AKT
signalling pathway [21]. These results suggested that GSK3L
and PKA were not involved in the phosphorylation of
htau412 at the AT100 epitope in the Xenopus oocyte model.
To ascertain that AT100 generation was not related to
GSK3L phosphorylation, di¡erent conditions where this en-
zyme is active or inactive were analysed.
To follow Tau phosphorylation by GSK3L, the appearance
of the typical phosphorylated AD2 epitope (similar to the
PHF-1 epitope) [22] was monitored. Htau412 was ¢rstly in-
jected in prophase I oocyte in the absence of progesterone
with or without LiCl, a common GSK3L inhibitor [16]. Ap-
pearance of AD2-immunoreactivity ¢rst occurred after 4 h
and htau412 exhibited an apparent Mr of 65 kDa (Fig. 2,
3LiCl). No AT100 immunoreactivity was observed in com-
parison to metaphase II extract (Fig. 1B). In the presence of
10 mM lithium, AD2 immunoreactivity was never observed
(Fig. 2, +LiCl). Furthermore, no 65 kDa variant was visual-
ised using the polyclonal M19G antibody, suggesting that
under these conditions, no phosphorylation occurred that
may induce conformational changes and higher Mr (Fig. 2,
+LiCl). Altogether, these data indicated that Xenopus GSK3L
is able to phosphorylate human htau412 at AD2 epitope (Fig.
2) but not to generate AT100 epitope.
During oocyte maturation, AT100-immunoreactivity was
obtained 5 h after progesterone stimulation (Fig. 3B). Thus,
to ascertain that GSK3L is not involved, oocyte maturation
was induced in the presence or not of LiCl. In oocytes stimu-
lated by progesterone in the presence of 10 mM LiCl, WS
appeared 1 h earlier than in control oocytes (Fig. 3A). This
result is in agreement with experiments where oocyte matura-
tion was analysed after microinjection of neutralising anti-
GSK3L antibodies [9]. Moreover, analysis of L-catenin
showed an accumulation of the protein at GVBD time in
control oocytes whereas the level of L-catenin was already
Fig. 3. E¡ect of the GSK3L inhibitor LiCl on AT100-immunoreac-
tivity during progesterone-induced maturation. A: E¡ect of LiCl
onto oocyte maturation. A time-course experiment of progesterone-
induced oocyte maturation was performed after Tau injection in the
presence (+) or not of LiCl (3). Maturation was assessed by WS
appearance (%). B: Immunoblotting analysis of AT100 immunoreac-
tivity. C: Immunoblotting analysis of L-catenin immunoreactivity
and quanti¢cation. In B and C, a time-course comparison was per-
formed between control oocytes (3LiCl) and oocytes subjected to
LiCl.
Fig. 4. E¡ect of PKAr on htau412 phosphorylation. A: E¡ect of
PKAr onto oocyte maturation. Oocytes were injected with PKAr 1 h
before htau412 microinjection with or without progesterone-contain-
ing medium. Tau proteins were injected into prophase I oocytes.
Maturation was assessed by WS appearance (%). Note that PKAr
injection did not allow for maturation of all oocytes [17] and that,
in the presence of LiCl, PKAr-induced oocyte maturation occurred
earlier. B: Htau412 phosphorylation was assessed with AD2 and
AT100 antibodies, and compared to metaphase II (pg+/PKAr3) or
to prophase I (pg3/PKAr3) oocytes. Killing of both PKA and
GSK3L activities was also performed (pg3/PKAr+/LiCl). AT100-
immunoreactivity was detected under all conditions of PKA inhibi-
tion.
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higher after 1 h of hormonal stimulation in LiCl-treated oo-
cytes (Fig. 3C). Both observations were in agreement with a
GSK3L inhibition in LiCl-containing medium. Furthermore,
when we analysed htau412 phosphorylation in such oocytes,
we observed that the events usually observed following pro-
gesterone addition still occurred in the presence of LiCl. How-
ever, the shift in htau412 revealed with the M19G antibody as
well as the AD2 and AT100 staining occurred 1 h earlier than
in control oocytes (Fig. 3B, data not shown). So, although
GSK3L was inhibited, the AT100 still appeared just after
GVBD suggesting that other kinases may be involved in
AT100 generation. It should be noted that similar results
were obtained using 20 mM LiCl, but at this concentration,
oocyte maturation after progesterone treatment occurred 90
min earlier than in control oocytes (data not shown).
Since it was shown that AT100 is generated in vitro after a
sequential phosphorylation of GSK3L and PKA, AT100-im-
munoreactivity was also investigated under di¡erent condi-
tions of PKA activation. In prophase I oocytes without pro-
gesterone treatment, PKA is active whereas it is inactive after
hormonal stimulation. Oocyte maturation is linked to PKA
inhibition [8,17]. Moreover, injection of PKAr led to oocyte
maturation (Fig. 4A). Under any of the conditions where
PKA was inhibited (progesterone stimulation and/or PKAr
subunit injection), Tau is highly phosphorylated leading to
the appearance of a high Mr variant at 69 kDa and AD2
and AT100 immunoreactivities (Fig. 4B). Finally, even when
a killing of both PKA and GSK3L activities was realized at
the same time (injection of PKAr in the presence of LiCl),
AT100-immunoreactivity was still detected (Fig. 4B). These
data indicated that PKA is not necessary for the AT100 epi-
tope in Xenopus oocytes.
4. Discussion
Neuropathologically, Alzheimer’s disease is characterised
by amyloid deposition and neuro¢brillary degeneration in
which accumulate bundles of PHFs constituted mainly of ab-
normally phosphorylated Tau proteins. What could be the
kinases responsible for the abnormal phosphorylation of
Tau proteins and especially at site recognised by one of the
only antibodies that specially recognises PHF-Tau, AT100
antibody?
AT100 binds to a conformation epitope including phos-
phorylated Thr212 and Ser214 [2]. Sequential phosphorylation
of Tau protein by GSK3L and PKA has been reported to
generate this epitope in vitro [2]. However, in the present
study, AT100 was never detected in prophase I-arrested oo-
cytes that contain high levels of PKA and GSK3L activities.
In that case, htau412 shifted to an apparent Mr lower than
those observed after progesterone stimulation. GSK3L seems
to be responsible for this intermediate state recognised by
AD2 since no shift and no staining was observed when pro-
phase I-arrested oocytes were incubated in LiCl-containing
medium. So, even if GSK3L was able to phosphorylate
htau412, AT100 could not appear. Our suggestion that neither
GSK3L nor PKA are involved in the genesis of AT100 epitope
in our model is heightened by the fact that these kinases are
inhibited when oocytes mature, i.e. when AT100 staining ap-
pears [8,9]. First, AT100 staining of htau412 was observed
when oocyte maturation was induced by the injection of
PKAr. This treatment inhibits endogenous PKA activity and
is su⁄cient to trigger maturation without hormonal stimu-
lation [8,17]. Moreover, using lithium, the common GSK3L
inhibitor [16], AT100 still appeared when progesterone stim-
ulation was performed. GSK3L inhibition was ascertained by
a faster maturation in which L-catenin accumulation occurred
earlier than in control oocytes. Furthermore, when oocyte
maturation is obtained after insulin stimulation instead of
progesterone, AT100-immunoreactivity was still observed.
This treatment also leads to GSK3L inhibition since insulin
acts through Akt activation [21]. Finally, co-transfection of
cDNAs of tau and a constitutively active form of GSK3L
[22] in COS cells did not allow for AT100 genesis (P.D. and
L.B., unpublished data). Altogether, these data clearly indi-
cated that GSK3L is not involved in AT100 epitope.
The present data disagreed with those previously reported
from in vitro experiments [2]. The sequential phosphorylation
of Tau protein was performed with human Tau 23 and the
presence of polyanionic factors such as heparin, tRNA or
poly-Glu was absolutely required to generate AT100 epitope
[2]. Moreover, several hours were needed for the puri¢ed ki-
nases to phosphorylate htau23 at the AT100 site.
Xenopus oocytes might be a more physiological model in
which the kinases involved in the abnormal phosphorylation
of Tau proteins could be characterised. Indeed, it is one of the
rare cells in which the phosphorylation of Tau is very close to
those occurring in AD. In fact, even if there is no endogenous
Tau protein in this cell, the phosphorylation of injected Tau
proteins as well as AT100 labelling occurred following stimu-
lation with progesterone, which is the natural inducer of meio-
sis. So, Xenopus oocytes provide new opportunities to charac-
terise signalling pathways (kinases or phosphatases) leading to
abnormal phosphorylation of Tau proteins and so to neuro-
degeneration observed in AD.
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